Blockade of mGluR5 glutamate receptors in the subthalamic nucleus ameliorates motor asymmetry in an animal model of Parkinson's disease

European Journal of Neuroscience

Volumn 23, Issue 1, 2006, Pages 151-160

  Phillips, Janice M ^a   Lam, Hoa A ^a   Ackerson, Larry C ^a   Maidment, Nigel T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Basal ganglia; Motor behavior; MPEP; Rat; STN

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; DOPAMINE; GLUTAMATE RECEPTOR; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR ANTAGONIST; OXIDOPAMINE; 6 METHYL 2 (PHENYLETHYNYL)PYRIDINE; 6-METHYL-2-(PHENYLETHYNYL)PYRIDINE; ADRENERGIC RECEPTOR BLOCKING AGENT; AMINO ACID RECEPTOR BLOCKING AGENT; METABOTROPIC RECEPTOR; PYRIDINE DERIVATIVE;

ADRENAL CORTEX; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; BRAIN REGION; CONTROLLED STUDY; DISEASE SEVERITY; DOPAMINE RELEASE; DOSE RESPONSE; DRUG EFFECT; ENTOPEDUNCULAR NUCLEUS; FOLLOW UP; INDWELLING CATHETER; LOW DRUG DOSE; MALE; MICROINJECTION; MOTOR PERFORMANCE; NEUROPSYCHOLOGICAL TEST; NONHUMAN; PARKINSON DISEASE; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; RAT; SENSORIMOTOR FUNCTION; SUBTHALAMIC NUCLEUS; ANIMAL; ANIMAL BEHAVIOR; COMPARATIVE STUDY; DISEASE MODEL; DRUG ANTAGONISM; DRUG INTERACTION; HEMISPHERIC DOMINANCE; METABOLISM; MOTOR ACTIVITY; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; TIME;

ANIMALS; BEHAVIOR, ANIMAL; DISEASE MODELS, ANIMAL; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; EXCITATORY AMINO ACID ANTAGONISTS; FUNCTIONAL LATERALITY; MALE; MOTOR ACTIVITY; OXIDOPAMINE; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; SUBTHALAMIC NUCLEUS; SYMPATHOLYTICS; TIME FACTORS;

EID: 33644955961     PISSN: 0953816X     EISSN: 14609568     Source Type: Journal    
DOI: 10.1111/j.1460-9568.2005.04550.x     Document Type: Article

References (49)

1. Abbott A. Wigmore MA. Lacey MG. 1997 Excitation of rat subthalamic nucleus neurons in vitro by activation of a group 1 metabotropic glutamate receptor BrainRes 766 162 167
2. Amalric M. Baunez C. Nieoullon A. 1995 Does the blockade of excitatory amino acid transmission in the basal ganglia simply reverse reaction time deficits induced by dopamine inactivation? BehavPharmacol 6 508 519
3. Awad H. Hubert GW. Smith Y. Levey AI. Conn PJ. 2000 Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus JNeurosci 20 7871 7879
4. Benazzouz A. Gross C. Feger J. Boraud T. Bioulac B. 1993 Reversal of rigidity and improvement in motor performance by subthalamic high frequency stimulation in MPTP-treated monkeys EurJNeurosci 5 382 389
5. Bergman H. Wichmann T. Karmon B. DeLong MR. 1994 The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism JNeurophysiol 72 507 520
6. Beurrier C. Congar P. Bioulac B. Hammond C. 1999 Subthalamic nucleus neurons switch from single-spike activity to burst-firing mode JNeurosci 19 599 609
7. Bradley SR. Standaert DG. Rhodes KJ. Rees HD. Testa CM. Levey AI. Conn PJ. 1999 Immunohistochemical localization of subtype 4a metabotropic glutamate receptors in the rat and mouse basal ganglia JCompNeurol 407 33 46
8. Breysse N. Amalric M. Salin P. 2003 Metabotropic glutamate 5 receptor blockade alleviates akinesia by normalizing activity of selective basal-ganglia structures in parkinsonian rats JNeurosci 23 8302 8309
9. Breysse N. Baunez C. Spooren W. Gasparini F. Amalric M. 2002 Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism JNeurosci 22 5669 5678
10. 5 receptors increase their efficacy in reversing Parkinsonian deficits in rats Neuropsychopharm 29 1451 1461
11. Conn PJ. Pin J-P. 1997 Pharmacology and functions of metabotropic glutamate receptors AnnRevPharmacolToxicol 37 205 237
12. Gasparini F. Lingenhohl K. Stoehr N. Flor PJ. Heinrich M. Vranesic I. Biolloz M. Allgeier H. Heckendorn R. Urwyler S. Varney MA. Johnson EC. Hess SD. Rao SP. Sacaan AI. Santori EM. Velicelebi G. Kuhn R. 1999 2-Methyl-7- (phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist Neuropharmacol 38 1493 1503
13. Greenamyre JT. O'Brien CF. 1991 M-methyl-D-aspartate antagonists in the treatment of Parkinson's disease ArchNeurol 48 977 981
14. Hassani OK. Mouroux M. Feger J. 1996 Increased subthalamic neuronal activity after nigral dopaminergic lesion independent of disinhibition via the globus pallidus Neuroscience 72 105 115
15. Henderson JM. Dunnett SB. 1998 Targeting the subthalamic nucleus in the treatment of parkinson's disease Brain ResBull 46 467 474
16. Hubert GW. Paquet M. Smith Y. 2001 Differential subcellular localization of mGluR1a and mGluR5 in the rat and monkey substantia nigra JNeurosci 21 1838 1847
17. Johnston RE. Schallert T. Becker JB. 1999 Akinesia and postural abnormality after unilateral dopamine depletion BehavBrRes 104 189 196 q2
18. Laitinen LV. Bergenheim AT. Hariz MI. 1992 Leksell's posteroventral pallidotomy in the treatment of Parkinson's disease JNeurosurg 76 53 61
19. Levy R. Hutchison WD. Lozano AM. Dostrovsky JO. 2000 High frequency synchronization of neuronal activity in the subthalamic nucleus of parkinsonian patients with limb tremor JNeurosci 20 7766 7775
20. Limousin P. Pollak P. Benazzouz A. Hoffmann D. Le Bas J-F. Broussolle E. Perrett JE. Benabid AL. 1995 Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation Lancet 345 91 95
21. MacInnes N. Messenger MJ. Duty S. 2004 Activation of group III metabotropic glutamate receptors in selected regions of the basal ganglia alleviates akinesia in the reserpine-treated rat BrJPharmacol 141 15 22
22. Magarinos-Ascone CM. Figueiras-Mendez R. Riva-Meana C. Cordoba-Fernandez A. 2000 Subthalamic neuron activity related to tremor and movement in Parkinson's disease EurJPharmacol 12 2597 2607
23. Marino MJ. Awad H. Poisik O. Wittmann M. Conn PJ. 2002b Localization and physiological roles of metabotropic glutamate receptors in the direct and indirect pathways of the basal ganglia Amino Acids 23 185 191
24. Marino MJ. Awad-Granko H. Ciombor KJ. Conn PJ. 2002a Haloperidol-induced alteration in the physiological actions of group I mGluRs in the subthalamic nucleus and the substantia nigra pars reticulate Neuropharmacol 43 147 159
25. Marino MJ. Williams Jr DL. O'Brien JA. Valenti O. McDonald TP. Clements MK. Wang R. DiLella AG. Hess F. Kinney GG. Conn PJ. 2003 Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment ProcNatlAcadSciUSA 100 13668 13673
26. Marino MJ. Wittman M. Bradley SR. Hubert GW. Smith Y. Conn PJ. 2001 Activation of Group I metabotropic glutamate receptors produces a direct excitation and disinhibition of GABAergic projection neurons in the substantia nigra pars reticulate JNeurosci 21 7001 7012
27. Mathiesen JM. Svendsen N. Brauner-Osborne H. Thomsen C. Ramirez MT. 2003 Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGluR4) by SIB-1893 and MPEP BrJPharmacol 138 1026 1030
28. Messenger MJ. Dawson LG. Duty S. 2002 Changes in metabotropic glutamate receptor 1-8 gene expression in the rodent basal ganglia motor loop following lesion of the nigrostriatal tract Neuropharmacol 43 261 271
29. Murphy NP. Maidment NT. 1999 Orphanin FF/nociceptin modulation of mesolimbic dopamine transmission determined by microdialysis JNeurochem 73 179 186
30. Ossowska K. Konieczny J. Wolfarth S. Wieronska J. Pilc A. 2001 Blockade of the metabotropic glutamate receptor subtype 5 (mGluR5) produces antiparkinsonian-like effects in rat Neuropharmacol 41 413 420
31. Ossowska K. Konieczyny J. Wardas J. Golembiowska K. Wolfarth S. Pilc A. 2002 The role of striatal metabotropic glutamate receptors in Parkinson's disease Amino Acids 23 193 198
32. Ossowska K. Lorenc-Koci E. Wolfarth S. 1994 Antiparkinsonian action of MK-801 on the reserpine-induced rigidity: a mechanomyographic analysis JNeural TransmParkDisDementSect 7 143 152
33. Paxinos G. Watson C. 1998 The Rat Brain in Stereotaxic Coordinates, 4th Edn. Academic Press San Diego, CA, USA
34. Phillips JM. Brown VJ. 1999 Reaction time performance following unilateral striatal dopamine depletion and lesions of the subthalamic nucleus in the rat EurJNeurosci 11 1003 1010
35. Phillips JM. Maidment NT. 2002 The subthalamic nucleus (STN) mediates the anti-Parkinsonian effect of MPEP in an animal model of Parkinson's disease SocNeurosciAbstr 885.7q3
36. 2A and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum JNeurochem 92 433 441
37. Rodriguez MC. Guridi OJ. Alverez L. Mewes K. Macias R. Vitek J. DeLong MR. Obeso JA. 1998 The subthalamic nucleus and tremor in Parkinson's disease MovDisord 13 111 118
38. Rouse ST. Marino MJ. Bradley SR. Awad H. Wittman M. Conn JP. 2000 Distribution and roles of metabotropic glutamate receptors in the basal ganglia motor circuit: implications for treatment of Parkinson's disease and related disorders PharmacolTherapeut 88 427 435
39. Schallert T. Fleming SM. Leasure JL. Tillerson JL. Bland ST. 2000 CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury Neuropharmacol 39 777 787
40. Schallert T. Tillerson JL. 1999 Intervention strategies for degeneration of dopamine neurons in Parkinsonism. In Emerich DF. Dean RL. Sanberg PR. Totowa NJ. (Eds) Central Nervous System Diseases Humana Press New York, USA, pp. 131 151
41. Schoepp DD. Jane DE. Monn AJ. 1999 Pharmacological agents acting at subtypes of metabotropic glutamate receptors Neuropharmacol 38 1431 1476
42. Spooren W. Ballard T. Gasparini F. Amalric M. Mutel V. Schreiber R. 2003 Insight into the function of Group I and Group II metabotropic glutamate (mGlu) receptors: behavioural characterization and implications for the treatment of CNS disorders BehavPharmacol 14 257 277
43. Spooren WPJM. Gasparini F. Bergmann R. Kuhn R. 2000 Effects of the prototypical mGlu5 receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine on rotarod, locomotor activity and rotational responses in unilateral 6-OHDA-lesioned rats EurJPharmacol 406 403 410
44. Starr MS. 1995 Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease Synapse 19 264 293
45. Testa CM. Standaert DG. Young AB. Penney JB. 1994 Metabotropic glutamate receptor mRNA expression in the basal ganglia of the rat JNeurosci 14 3005 3018
46. Valenti O. Mannaioni G. Seabrook GR. Conn J. Marino MJ. 2005 Group III metabotropic-glutamate-receptor-mediated modulation of excitatory transmission in rodent substantia nigra pars compacta dopamine neurons JPharmacolExpTher 313 1296 1304
47. Valenti O. Marino MJ. Wittmann M. Lis E. Dilella AG. Kinney GG. Conn PJ. 2003 Group III metabotropic glutamate receptor-mediated modulation of the striatopallidal synapse JNeurosci 23 7218 7226
48. Wichmann T. DeLong MR. 1997 Physiology of the basal ganglia and pathophysiology of movement disorders of basal ganglia origin. In Watts RL. (Ed.) Movement Disorders: Neurological Principles and Practice McGraw-Hill
49. Wittmann M. Marino MJ. Conn PJ. 2002 Dopamine modulates the function of group II and group III metabotropic glutamate receptors in the substantia nigra pars reticulata JPharmacolExpTher 302 433 441